These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

36 related articles for article (PubMed ID: 23903094)

  • 1. Therapeutics: Disrupting a survival signal.
    McCarthy N
    Nat Rev Cancer; 2013 Sep; 13(9):608-9. PubMed ID: 23903094
    [No Abstract]   [Full Text] [Related]  

  • 2. CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer.
    Neesse A; Frese KK; Bapiro TE; Nakagawa T; Sternlicht MD; Seeley TW; Pilarsky C; Jodrell DI; Spong SM; Tuveson DA
    Proc Natl Acad Sci U S A; 2013 Jul; 110(30):12325-30. PubMed ID: 23836645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete pathological response after chemotherapy alone in a patient with pancreatic adenocarcinoma.
    Carbonell S; Espinosa J; Zarco A; de-Madaria E; de la Hoz J; Yuste A; Payá A; Lluís F
    Pancreas; 2012 May; 41(4):657-9. PubMed ID: 22504386
    [No Abstract]   [Full Text] [Related]  

  • 4. Connective tissue growth factor-specific antibody attenuates tumor growth, metastasis, and angiogenesis in an orthotopic mouse model of pancreatic cancer.
    Aikawa T; Gunn J; Spong SM; Klaus SJ; Korc M
    Mol Cancer Ther; 2006 May; 5(5):1108-16. PubMed ID: 16731742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cavitary pulmonary metastases of pancreas cancer.
    Tamura T; Nakazawa K; Kagohashi K; Kurishima K; Satoh H
    J Gastrointest Cancer; 2013 Jun; 44(2):222-4. PubMed ID: 22875583
    [No Abstract]   [Full Text] [Related]  

  • 6. [nab-Paclitaxel as new therapeutic option for pancreatic cancer].
    Michl P
    Z Gastroenterol; 2013 Nov; 51(11):1329-30. PubMed ID: 24243574
    [No Abstract]   [Full Text] [Related]  

  • 7. A New Scalpel for the Treatment of Pancreatic Cancer: Targeting Stromal-Derived STAT3 Signaling.
    Cowan RW; Maitra A; Rhim AD
    Gastroenterology; 2015 Dec; 149(7):1685-8. PubMed ID: 26526714
    [No Abstract]   [Full Text] [Related]  

  • 8. Compression of pancreatic tumor blood vessels by hyaluronan is caused by solid stress and not interstitial fluid pressure.
    Chauhan VP; Boucher Y; Ferrone CR; Roberge S; Martin JD; Stylianopoulos T; Bardeesy N; DePinho RA; Padera TP; Munn LL; Jain RK
    Cancer Cell; 2014 Jul; 26(1):14-5. PubMed ID: 25026209
    [No Abstract]   [Full Text] [Related]  

  • 9. Response to Chauhan et Al.: interstitial pressure and vascular collapse in pancreas cancer-fluids and solids, measurement and meaning.
    DelGiorno KE; Carlson MA; Osgood R; Provenzano PP; Brockenbough JS; Thompson CB; Shepard HM; Frost GI; Potter JD; Hingorani SR
    Cancer Cell; 2014 Jul; 26(1):16-7. PubMed ID: 25026210
    [No Abstract]   [Full Text] [Related]  

  • 10. Irreversible electroporation: a novel pancreatic cancer therapy.
    Weiss MJ; Wolfgang CL
    Curr Probl Cancer; 2013; 37(5):262-5. PubMed ID: 24331180
    [No Abstract]   [Full Text] [Related]  

  • 11. The case for a stratified application of targeted agents against pancreatic cancer.
    Bijlsma MF
    EBioMedicine; 2021 May; 67():103344. PubMed ID: 33910122
    [No Abstract]   [Full Text] [Related]  

  • 12. Harnessing immune responses in the tumor microenvironment: all signals needed.
    Le DT; Jaffee EM
    Clin Cancer Res; 2013 Nov; 19(22):6061-3. PubMed ID: 24097857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of a preclinical model of pancreas cancer to identify potential candidates for rapalogue therapy.
    Takeuchi KK; Crawford HC
    Gut; 2014 Sep; 63(9):1379-80. PubMed ID: 24966285
    [No Abstract]   [Full Text] [Related]  

  • 14. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
    Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
    Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pancreatic cancer: a major challenge in oncology].
    Fölsch UR; Schäfer H
    Med Klin (Munich); 2004 Apr; 99(4):183-4. PubMed ID: 15085287
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase IIA trial testing erlotinib as an intervention against intraductal pancreatic mucinous neoplasms.
    Lipkin S; Lee J; Imagawa D; Hewitt SM; Tucker C; Zell JA; Wong V; Garcia A; Gonzalez R; Della Zanna G; Richmond E; Rodriguez LM; Bigg M; Schnoll-Sussmans F; Meyskens F
    Cancer Prev Res (Phila); 2011 Apr; 4(4):512-3. PubMed ID: 21464031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal antibody therapies targeting pancreatic ductal adenocarcinoma.
    Engelhardt K; Riley C; Cooke L; Mahadevan D
    Curr Drug Discov Technol; 2006 Dec; 3(4):231-43. PubMed ID: 17430101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A newly developed anti-Mucin 13 monoclonal antibody targets pancreatic ductal adenocarcinoma cells.
    Nishii Y; Yamaguchi M; Kimura Y; Hasegawa T; Aburatani H; Uchida H; Hirata K; Sakuma Y
    Int J Oncol; 2015 Apr; 46(4):1781-7. PubMed ID: 25672256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pancreatic Adenocarcinoma Therapeutics Targeting RTK and TGF Beta Receptor.
    Yang HH; Liu JW; Lee JH; Harn HJ; Chiou TW
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ASO Author Reflections: Neoadjuvant Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma-Predictors of Disease Progression and Performance Status Decline.
    Paniccia A; Zureikat A
    Ann Surg Oncol; 2020 Aug; 27(8):2972-2973. PubMed ID: 32124127
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.